Autologous Transplantation Improves Survival Rates for Follicular Lymphoma Patients Who Relapse within 2-Years of Chemoimmunotherapy: A Multi-Centre Retrospective Analysis of Consecutively Treated Patients in the Real World
Bibliographic record
Abstract
Abstract Introduction: Although rituximab-based chemoimmunotherapy (RChemo) significantly improves overall survival (OS) for follicular lymphoma (FL), approximately 20% of patients experience initial time to progression (TTP1) of ≤2 years (early relapse) and relatively poor OS. We conducted a retrospective study to evaluate OS rates for patients with early relapse who were treated with or without high dose therapy and autologous stem cell transplantation (ASCT). Methods: A retrospective, multi-centre, study was conducted to identify all patients aged 18 to 70 years who were consecutively diagnosed in Alberta with grade 1 to 3a FL prior to 2011, and eventually received RChemo as their initial systemic therapy. Patient characteristics including Follicular Lymphoma International Prognostic Index (FLIPI) factors at RChemo, treatment details including Rituximab-maintenance (RMaintenance), TTP post-RChemo, frequency of transformation at relapse, and treatments after relapse were obtained. TTP and OS following RChemo and ASCT were evaluated in univariate and multivariate analyses. Results: Interrogation of the Alberta Cancer Registry identified 397 patients diagnosed with FL prior to 2011 who received RChemo. At a median follow-up of 92 months (3-179), 148 (37.3%) of the 397 patients relapsed from RChemo, including 82 (20.7%) with early relapse ≤2years and 66 (16.6%) with late relapse >2years. Table 1.0 lists characteristics of the 148 patients who relapsed after RChemo. Seventy-one (48.0%) patients underwent ASCT at relapse. Conditioning regimens included high dose melphalan (n=49, 69%, of whom 35 also received total body irradiation), BEAM (carmustine, etoposide, cytarabine, melphalan, n=21, 29.6%), and CBV (cyclophosphamide, BCNU, VP-16, n=1, 1.4%). In total, there were 29.1% (n=43) deaths following relapse, with majority of deaths due to FL (n=32, 74.4%). The projected 10-year OS following first RChemo was 93.8% in those with no relapse, 76.4% with late relapse, and 56.9% with early relapse (logrank p Conclusions: Our study strongly suggests that the use of ASCT for FL patients who relapse within 2 years of RChemo is associated with improved OS. Download : Download high-res image (179KB) Download : Download full-size image Disclosures Peters: Gilead: Honoraria; Janssen: Honoraria; Lundbeck: Honoraria; Roche: Honoraria; Abbvie: Honoraria. Stewart: Merck: Honoraria; Janssen: Honoraria; Abbvie: Honoraria; Gilead: Honoraria; Seattle Genetics: Honoraria; BMS: Honoraria; Roche: Honoraria; Amgen: Honoraria; Servier: Honoraria; Lundbeck: Honoraria.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".